A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

General Information

Summary The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
Description Not Provided
Clinical trials phase Phase 1
Start date (estimated) 2017-07-05
End date (estimated) 2018-02-15
Clinical feature
Label Diabetes Mellitus, Type 1
Link http://purl.obolibrary.org/obo/OMIT_0005198

Administrative Information

NCT number NCT03162926
Other study identifiers
Name VC02-102
Source weblink https://clinicaltrials.gov/ct2/show/record/NCT03162926
Regulatory body approval
Name Food and Drug Administration (FDA)
United States
Public contact
Email info@viacyte.com
Sponsors ViaCyte

Cell Line

Stem cell lines obtained from


Recruitment Status Completed
Estimated number of participants 3